Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair - PubMed (original) (raw)
Review
. 1994 Jan 14;269(2):787-90.
Affiliations
- PMID: 8288625
Free article
Review
Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair
G Chu. J Biol Chem. 1994.
Free article
Abstract
The anticancer drug cisplatin provokes a complex response in the cell. A lethal dose of the drug kills cells primarily by forming DNA adducts, causing G2 arrest in the cell cycle, and then triggering apoptosis. A sublethal dose induces drug resistance by several mechanisms, including changes in drug uptake and efflux, glutathione and metallothionein levels, and DNA repair. Cisplatin-DNA adducts bind several cellular proteins, including some that enhance survival of the cell by mediating DNA repair and others that hasten its death by conferring sensitivity to the drug.
Similar articles
- Molecular basis of cis-diamminedichloroplatinum(II) resistance: a review.
Chao CC. Chao CC. J Formos Med Assoc. 1996 Dec;95(12):893-900. J Formos Med Assoc. 1996. PMID: 9000804 Review. - The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin.
Mello JA, Acharya S, Fishel R, Essigmann JM. Mello JA, et al. Chem Biol. 1996 Jul;3(7):579-89. doi: 10.1016/s1074-5521(96)90149-0. Chem Biol. 1996. PMID: 8807890 - The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts.
Vaisman A, Varchenko M, Umar A, Kunkel TA, Risinger JI, Barrett JC, Hamilton TC, Chaney SG. Vaisman A, et al. Cancer Res. 1998 Aug 15;58(16):3579-85. Cancer Res. 1998. PMID: 9721864 - Mechanisms of resistance to cisplatin.
Kartalou M, Essigmann JM. Kartalou M, et al. Mutat Res. 2001 Jul 1;478(1-2):23-43. doi: 10.1016/s0027-5107(01)00141-5. Mutat Res. 2001. PMID: 11406167 Review. - Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells.
Perego P, Gatti L, Righetti SC, Beretta GL, Carenini N, Corna E, Dal Bo L, Tinelli S, Colangelo D, Leone R, Apostoli P, Lombardi L, Beggiolin G, Piazzoni L, Zunino F. Perego P, et al. Int J Cancer. 2003 Jul 10;105(5):617-24. doi: 10.1002/ijc.11140. Int J Cancer. 2003. PMID: 12740909
Cited by
- NEAT1_2-SFPQ axis mediates cisplatin resistance in liver cancer cells in vitro.
Ru Y, Chen XJ, Guo WZ, Gao SG, Qi YJ, Chen P, Feng XS, Zhang SJ. Ru Y, et al. Onco Targets Ther. 2018 Sep 11;11:5695-5702. doi: 10.2147/OTT.S163774. eCollection 2018. Onco Targets Ther. 2018. PMID: 30254462 Free PMC article. - Copper transporter 2 regulates endocytosis and controls tumor growth and sensitivity to cisplatin in vivo.
Blair BG, Larson CA, Adams PL, Abada PB, Pesce CE, Safaei R, Howell SB. Blair BG, et al. Mol Pharmacol. 2011 Jan;79(1):157-66. doi: 10.1124/mol.110.068411. Epub 2010 Oct 7. Mol Pharmacol. 2011. PMID: 20930109 Free PMC article. - Stress proteins in subcellular structures upon cisplatin treatment and heat shock.
Mavletova DA, Dvorkin GA. Mavletova DA, et al. Dokl Biochem Biophys. 2003 May-Jun;390:157-9. doi: 10.1023/a:1024416408103. Dokl Biochem Biophys. 2003. PMID: 12959069 No abstract available. - Pulmonary delivery of cisplatin-hyaluronan conjugates via endotracheal instillation for the treatment of lung cancer.
Xie Y, Aillon KL, Cai S, Christian JM, Davies NM, Berkland CJ, Forrest ML. Xie Y, et al. Int J Pharm. 2010 Jun 15;392(1-2):156-63. doi: 10.1016/j.ijpharm.2010.03.058. Epub 2010 Apr 2. Int J Pharm. 2010. PMID: 20363303 Free PMC article. - Concordant and opposite roles of DNA-PK and the "facilitator of chromatin transcription" (FACT) in DNA repair, apoptosis and necrosis after cisplatin.
Sand-Dejmek J, Adelmant G, Sobhian B, Calkins AS, Marto J, Iglehart DJ, Lazaro JB. Sand-Dejmek J, et al. Mol Cancer. 2011 Jun 16;10:74. doi: 10.1186/1476-4598-10-74. Mol Cancer. 2011. PMID: 21679440 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources